Abstract: Objective To choose drug-coated balloon combined with Turbohawk plaque volume reduction therapy in patients with lower extremity arteriosclerosis occlusive disease,and compare it with DCB therapy alone to analyze the safety and effectiveness of its treatment.
Methods The subjects of the study were 84 ASO patients admitted to our hospital from August 2014 to August 2018.Patients in the simple group received DCB expansion therapy(40 cases),and patients in the combined group received DCB expansion combined with DA volume reduction therapy(44 cases).Observation indicators include the incidence of perioperative adverse reactions,follow-up indicators and prognostic indicators.
Results The incidence of adverse reactions in the combination group was significantly lower than that in the simple group [(2.3%) vs(12.5%)](P<0.05).At 24 months postoperatively,the Rutherford grade [(1.31±0.68) vs(2.86±0.82)],late lumen loss(LLL) [(0.41±0.76)mm) vs(0.98±0.87)mm] and restenosis rate (6.8% vs. 25.0%) in the combination group were significantly lower than those in the simple group,while the ankle-brachial index(ABI) [(0.87±0.14) vs(0.65±0.14)],the minimum diameter of the target vessel(MLD) [(4.18±0.84)mm vs(3.17±0.55)mm].The target lesion revascularization rate(TLR) (2.3% vs. 15.0%) was significantly better than that of the simple group(P<0.05).The improvement rate of walking disorder (72.7% vs. 42.5%) and 6-minute walking distance [(44.23±9.24)m vs(27.60±8.81)m] in the combined group were significantly better than those in the simple group(P<0.05).
Conclusion The use of DCB combined with DA in lower extremity arteriosclerosis occlusive disease has the advantages of safety,efficiency and stability.It can effectively maintain sufficient vascular lumen and control lumen loss in patients and restenosis rate.

Key words: drug-coated balloon, atherectomy, lower extremity arteriosclerosis occlusion, restenosis rate